

## Supplementary Online Content

Mayadev JS, Enserro D, Lin YG, et al. Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer. *JAMA Oncol*. Published online November 27, 2019. doi:10.1001/jamaoncol.2019.3857

**eTable 1.** Grade  $\geq 3$  Treatment-Related Adverse Events During Ipilimumab

**eTable 2.** Analysis Relating HPV Genotype and HLA-A\*0201 Status Variables to PFS

**eTable 3.** Analysis Relating HPV Genotype and HLA-A\*0201 Status Variables to OS

**eTable 4.** Analysis Relating PBMC PD-1 Expression Change From Baseline to Post-CRT to PFS

**eTable 5.** Analysis Relating PBMC PD-1 Expression Change From Baseline to Post-CRT to OS

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Grade  $\geq 3$  Treatment-Related Adverse Events During Ipilimumab

System Organ Class/Term	Treatment/Adverse Event Grade			
	Ipilimumab 3 mg/kg every 3 weeks		Ipilimumab 10 mg/kg every 3 weeks	
	3	$\geq 4$	3	$\geq 4$
<b>Blood/Lymphatics</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>
Anemia	1	0	1	0
<b>Gastrointestinal</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>
Abdominal pain	0	0	1	0
Nausea	1	0	0	0
Vomiting	1	0	0	0
<b>General and administration site</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>
Fatigue	1	0	0	0
<b>Infections/infestations</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>
Urinary tract infection	1	0	0	0
<b>Investigations</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>0</b>
Lipase increased	0	0	1	0
Lymphocyte count decreased	0	0	2	0
Neutrophil count decreased	0	0	1	0
Platelet count decreased	0	0	1	0
<b>Nervous system</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>
Cognitive disturbance	1	0	0	0
<b>Renal/urinary</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>
Urinary tract obstruction	0	0	1	0
<b>Skin/subcutaneous</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>

	Treatment/Adverse Event Grade			
	Ipilimumab 3 mg/kg every 3 weeks		Ipilimumab 10 mg/kg every 3 weeks	
System Organ Class/Term	3	≥4	3	≥4
Rash maculo-papular	0	0	1	0

**eTable 2. Analysis Relating HPV Genotype and HLA-A\*0201 Status Variables to PFS**

<b>Status</b>	<b>Variable</b>	<b>PFS events</b>	<b>N at risk</b>	<b>HR</b>	<b>95% CI LL</b>	<b>95% CI UL</b>	<b>p-value</b>
Positive	HLA-A0201	3	20	0.796	0.072	8.785	0.8523
Positive	HPV16	3	20	0.390	0.035	4.307	0.4424
Positive	HPV18	3	20	3.620	0.325	40.277	0.2953

**eTable 3. Analysis Relating HPV Genotype and HLA-A\*0201 Status Variables to OS**

<b>Status</b>	<b>Variable</b>	<b>OS events</b>	<b>N at risk</b>	<b>HR</b>	<b>95% CI LL</b>	<b>95% CI UL</b>	<b>p-value</b>
Positive	HLA-A0201	2	20	1.604	0.100	25.677	0.7386
Positive	HPV16	2	20	0.771	0.048	12.347	0.8544
Positive	HPV18	2	20	6.940	0.428	112.549	0.1729

**eTable 4.** Analysis Relating PBMC PD-1 Expression Change From Baseline to Post-CRT to PFS

<b>Change</b>	<b>TR Variable</b>	<b>PFS events</b>	<b>N at risk</b>	<b>HR</b>	<b>95% CI LL</b>	<b>95% CI UL</b>	<b>p-value</b>
CRT - Baseline	% CD4 PD1+	3	19	1.009	0.902	1.129	0.8766
CRT - Baseline	% CD8 PD1+	3	19	0.994	0.845	1.170	0.9436

**eTable 5.** Analysis Relating PBMC PD-1 Expression Change From Baseline to Post-CRT to OS

<b>Change</b>	<b>TR Variable</b>	<b>OS events</b>	<b>N at risk</b>	<b>HR</b>	<b>95% CI LL</b>	<b>95% CI UL</b>	<b>p-value</b>
CRT - Baseline	% CD4 PD1+	2	19	0.975	0.851	1.117	0.7148
CRT - Baseline	% CD8 PD1+	2	19	1.015	0.832	1.238	0.8846